Table 1.
Clinical information of hepatocellular carcinoma (HCC) patients enrolled in this study.
| Sample ID | Age (Y) | Gender | Cirrhosis | Etiology | Tumor number | Cumulative tumor size (cm) | BCLC Stage | AJCC Stage | Within Milan Criteria |
|---|---|---|---|---|---|---|---|---|---|
| HCC01 | 84 | Male | No | idiopathic | 1 | 7.1 | B | 1b | No |
| HCC02 | 82 | Female | Yes | HCV | 1 | 3.6 | A | 1b | Yes |
| HCC03 | 73 | Male | Yes | HCV | 1 | 2.8 | A | 1b | Yes |
| HCC04 | 63 | Male | Yes | NAFLD/HCV | 1 | 2.4 | C | 4b | No |
| HCC05 | 60 | Female | Yes | HCV | 1 | 5.4 | A | 1b | No |
| HCC06 | 70 | Male | Yes | HCV | 1 | 2.2 | A | 1b | Yes |
| HCC07 | 61 | Male | Yes | HCV | No record | N/A | C | 4b | No |
| HCC08 | 75 | Male | Yes | NASH | 2 | 5.5 | B | 3b | Yes |
| HCC09 | 53 | Male | Yes | EtOH | 1 | 3.4 | A | 1b | Yes |
| HCC10 | 73 | Male | No | NASH | 1 | 13.5 | A | 1b | No |
| HCC11 | 73 | Male | Yes | NASH | 4 | 13.5 | C | 4b | No |
| HCC12 | 63 | Female | Yes | HBV | 1 | 7.9 | B | 3a | No |
| HCC13 | 61 | Male | Yes | HBV | infiltrative | 5.5 | C | 3b | No |
| HCC14 | 71 | Male | Yes | HCV | 1 | 2.1 | A | 1b | Yes |
| HCC15 | 53 | Male | No | HBV | Multiple >10 | 38.3 | C | 3b | No |
| HCC16 | 63 | Male | Yes | HCV | 3 | 7.5 | D | 4b | No |
| HCC17 | 78 | Male | No | idiopathic | 1 | 3.7 | A | 1b | Yes |
| HCC18 | 73 | Male | Yes | HCV | 1 | 4.2 | A | 1b | Yes |
| HCC19 | 56 | Female | Yes | HCV | 2 | 6.8 | A | 2 | No |
| HCC20 | 59 | Male | Yes | HCV/EtOH | 1 | 6.2 | C | 2 | No |
ALD, alcoholic liver disease; AJCC, American Joint Committee on Cancer; BCLC, Barcelona clinic liver cancer; HBV, hepatitis B virus; HCV, Hepatitis C virus; NAFLD, nonalcoholic fatty liver disease.